GlassScriptPhysician profile
Rupan Bose
NPI 1255835799
$5,414.62
in general payments reported to CMS, 2019-2025
31 companies · $37.04 in 2025
The $37.04 reported for 2025 was less than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,003 · 2022: $1,130 · 2023: $2,613 · 2024: $631 · 2025: $37.04.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,911 · Education: $245 · Grant: $125.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,911.34 |
| Education | $244.99 |
| Grant | $125.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $729.65 | 2021-2023 | Thoratec Heartmate 3 Lvas Implant Kit, Optis, Gallant |
| Boston Scientific Corporation | $717.62 | 2021-2025 | Ekosonic, General - Therapies, Lux-Dx Insertable Cardiac Monitor |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $419.38 | 2021-2024 | Lifevest |
| Pfizer INC. | $407.54 | 2021-2024 | |
| Amgen INC. | $364.17 | 2021-2023 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $320.93 | 2023-2024 | Camzyos |
| Abiomed | $316.46 | 2021-2023 | Impella |
| Novartis Pharmaceuticals Corporation | $276.25 | 2021-2023 | |
| Inari Medical, INC. | $214.13 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Janssen Pharmaceuticals, INC | $180.92 | 2022-2024 | Xarelto |
| Scpharmaceuticals INC. | $148.54 | 2023-2024 | |
| Cvrx, INC. | $142.85 | 2023 | Barostim Neo System |
| Shockwave Medical, INC | $142.76 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Biotronik INC. | $129.74 | 2022 | |
| Merck Sharp & Dohme LLC | $114.83 | 2023 | Verquvo |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $104.20 | 2021-2023 | Farxiga |
| Chiesi USA, INC. | $77.83 | 2021-2022 | |
| Edwards Lifesciences Corporation | $72.10 | 2022-2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| United Therapeutics Corporation | $69.24 | 2021-2023 | Tyvaso |
| Regeneron Healthcare Solutions, INC. | $62.88 | 2022-2023 | Evkeeza |
| Novo Nordisk INC | $60.43 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $59.12 | 2023 | Jardiance |
| Kiniksa Pharmaceuticals, LTD. | $56.13 | 2023 | Arcalyst |
| Abbvie INC. | $43.85 | 2021-2022 | |
| Kestra Medical Technology Services, INC. | $42.35 | 2023 | Assure Wcd |
| Kiniksa Pharmaceuticals International, Plc | $29.41 | 2024 | Arcalyst |
| Terumo Medical Corporation | $28.42 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $23.69 | 2021 | |
| Philips North America LLC | $20.34 | 2022 | |
| Actelion Pharmaceuticals US, INC. | $19.77 | 2021 | |
| Baxter Healthcare | $19.09 | 2023 | Hillrom - Carnation Ambulatory Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rupan Bose listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.